Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Metrics to compare | GENF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENFPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −2.8x | −0.6x | |
PEG Ratio | 0.18 | −0.01 | 0.00 | |
Price/Book | 7.9x | 1.5x | 2.6x | |
Price / LTM Sales | 11.4x | 11.6x | 3.1x | |
Upside (Analyst Target) | - | 330.5% | 48.7% | |
Fair Value Upside | Unlock | 27.0% | 7.7% | Unlock |